Connect Biopharma starts Phase 2, awaits Simcere China NDA amid revenue cliff

Connect Biopharma Holdings Limited (NASDAQ: CNTB) - quick company snapshot and income-statement takeaways.

What's happening inside the company
* Clinical progress: presented supportive clinical and preclinical rademikibart data at major conferences; initiated two Phase 2 acute-exacerbation trials (asthma and COPD). Topline data expected in first half of 2026.
* China partner activity: Simcere submitted an NDA for rademikibart for atopic dermatitis in July 2025; Connect is eligible for remaining milestone payments up to approximately $110 million plus royalties (tiered, up to low double-digits). One $8M milestone lapsed in 2025.
* Corporate changes: announced termination of ADR program and plan to substitute-list ordinary shares on Nasdaq (ADSs to be exchanged one-for-one); relocated U.S. HQ and recognized a right-of-use lease asset/liability; Board expanded by one director in July 2025.
* Cost and structure actions: previously paid severance related to 2024 executive reorganization; share-based compensation methodology changed to Black‑Scholes starting Jan 1, 2025.

Income statement - positives
* Company continues to convert partnership activity into cash (historical upfront + milestones from Simcere) and has potential upside from remaining milestones and future royalties.
* Rademikibart development is advancing (Phase 2 trials started), supporting R&D spend as deliberate investment in clinical progress.
* Management states cash, cash equivalents and short-term investments (~$71.8M) are sufficient to meet anticipated cash requirements for at least one year from filing date.

Income statement - negatives
* Revenue cliff: License & collaboration revenue fell from $24.116M (Q2 2024) to $48K (Q2 2025) after prior upfront/milestone recognition - near-term product revenue is effectively nil.
* Material operating loss and cash burn: Q2 2025 net loss $(12.9)M (vs net income $14.847M in Q2 2024); six‑month net loss $(23.171)M (vs net income $6.154M). Operating cash used YTD $22.55M.
* Growing R&D outlays: R&D expense increased (Q2 2025: $8.773M vs Q2 2024: $5.348M) driven by rademikibart development - accelerates cash consumption.
* One milestone lapsed (~$8M) - reduces near-term non-dilutive cash potential and increases reliance on remaining milestones/royalties and financing options.

Key financial statistics (from Form 10‑Q, six months ended June 30, 2025)
* License & collaboration revenue: $48 (three months) / $48 (six months) - prior year same periods $24,116 / $24,116.
* Research & development expense: $8,773 (Q2 2025) ; $15,406 (six months 2025). Rademikibart-related costs Q2: $5,753 vs $1,412 in Q2 2024.
* General & administrative expense: $4,699 (Q2 2025); $9,513 (six months 2025).
* Total operating expenses: $13,472 (Q2 2025); $24,919 (six months 2025).
* Loss from operations: $(13,424) (Q2 2025); $(24,871) (six months 2025).
* Other income, net: $580 (Q2 2025); $1,809 (six months 2025) - down vs prior year due to lower interest and subsidies.
* Net (loss) income: $(12,899) (Q2 2025); $(23,171) (six months 2025). Prior year: $14,847 and $6,154 respectively.
* Net (loss) per ordinary share, basic/diluted: $(0.23) Q2 2025; $(0.42) six months 2025. Weighted-average shares basic ~55,498 (Q2).
* Cash & cash equivalents: $40,632 (June 30, 2025) vs $78,232 (Dec 31, 2024). Short-term investments: $31,136 (June 30, 2025). Combined cash + short-term investments ≈ $71.8M.
* Total assets: $82,725; total liabilities: $11,383; total shareholders' equity: $71,342 (June 30, 2025).
* Operating cash flow, six months: net cash used in operating activities $(22,550).
* Investing cash flow, six months: net cash used $(15,512) (mostly purchases of short-term investments).
* Outstanding stock options: 13,898,102 (weighted-average exercise price $2.23). Unrecognized share‑based compensation ~$9.0M to be recognized over ~3.0 years.
* Income tax expense (three / six months): $55K / $109K; effective tax rate roughly 0% due to full valuation allowance against deferred tax assets.

Bottom line - what to watch
* Clinical readouts (Phase 2 topline expected H1 2026) and Simcere's China NDA outcome are the primary value drivers - success could unlock milestone payments and royalties.
* Near-term risks: revenue is minimal absent milestone recognition; R&D ramp and existing overhead mean continued cash burn. Cash + short-term investments (~$71.8M) provide runway management expects for at least one year, but continued spending and possible delays could require capital raises or partnerships.
* Corporate moves (ADR termination, substitution listing, HQ relocation, board addition) signal a U.S.-centric posture but also add transition complexity for investors.
* Recommendation: monitor upcoming clinical milestones, Simcere regulatory progress, quarterly burn and milestone receipts - these events will materially affect valuation and financing needs.

Source: Connect Biopharma Holdings Limited - Form 10‑Q for the quarter ended June 30, 2025 (filed Aug 13, 2025).